First Regular Session Seventieth General Assembly STATE OF COLORADO

REREVISED

This Version Includes All Amendments Adopted in the Second House

LLS NO. 15-0786.01 Kristen Forrestal x4217

HOUSE BILL 15-1214

HOUSE SPONSORSHIP

Singer,

SENATE SPONSORSHIP

Cooke,

House Committees

Public Health Care & Human Services

Senate Committees

State, Veterans, & Military Affairs

A BILL FOR AN ACT

101 CONCERNING OPIOID ANALGESICS WITH ABUSE-DETERRENT 102 PROPERTIES.

Bill Summary

(Note: This summary applies to this bill as introduced and does not reflect any amendments that may be subsequently adopted. If this bill passes third reading in the house of introduction, a bill summary that applies to the reengrossed version of this bill will be available at http://www.leg.state.co.us/billsummaries.)

The bill prohibits an opioid analgesic drug product that is not abuse-deterrent to be substituted for an abuse-deterrent opioid analgesic drug product if a health care provider prescribes an abuse-deterrent opioid analgesic drug product to a patient and the prescription includes the instructions "dispense as written". A carrier must cover the abuse-deterrent opioid analgesic drug product at the lowest cost-sharing

SENATE d Reading Unamended April 21, 2015

SENATE Amended 2nd Reading April 20, 2015

HOUSE 3rd Reading Unamended March 16, 2015

> HOUSE Amended 2nd Reading March 13, 2015

level as an opioid analgesic drug product. A carrier cannot require treatment failure with an opioid analgesic drug product that is not abuse-deterrent prior to providing coverage for the abuse-deterrent opioid analgesic drug product if the prescribing health care provider determines that the covered person would benefit from the abuse-deterrent opioid analgesic drug product.

Be it enacted by the General Assembly of the State of Colorado: 1 2 **SECTION 1.** In Colorado Revised Statutes, add 10-16-124.7 as 3 follows: 4 10-16-124.7. Opioid analysics with abuse-deterrent properties 5 - study - definitions. (1) THE GOVERNOR SHALL DIRECT THE COLORADO 6 CONSORTIUM FOR PRESCRIPTION DRUG ABUSE PREVENTION TO STUDY THE 7 BARRIERS TO __ THE USE OF ABUSE-DETERRENT OPIOID ANALGESIC DRUG 8 PRODUCTS AS A WAY TO REDUCE ABUSE AND DIVERSION OF OPIOID DRUG 9 PRODUCTS. ON OR BEFORE JANUARY 15, 2017, THE CONSORTIUM SHALL 10 REPORT ITS FINDINGS TO THE PUBLIC HEALTH CARE AND HUMAN SERVICES 11 COMMITTEE AND THE HEALTH, INSURANCE, AND ENVIRONMENT 12 COMMITTEE OF THE HOUSE OF REPRESENTATIVES AND THE HEALTH AND 13 HUMAN SERVICES COMMITTEE OF THE SENATE, OR THEIR SUCCESSOR 14 COMMITTEES. 15 (2) Moneys from the general fund shall not be used for 16 THE IMPLEMENTATION OF THIS SECTION. 17 (3) AS USED IN THIS SECTION: 18 "ABUSE-DETERRENT OPIOID ANALGESIC DRUG PRODUCT" (a) 19 MEANS A BRAND OR GENERIC OPIOID ANALGESIC DRUG PRODUCT 20 APPROVED BY THE UNITED STATE FOOD AND DRUG ADMINISTRATION 21 WITH ABUSE-DETERRENCE LABELING CLAIMS THAT INDICATE THAT THE 22 DRUG PRODUCT IS EXPECTED TO RESULT IN A MEANINGFUL REDUCTION IN

-2-

1	ABUSE.
2	
3	(b) "OPIOID ANALGESIC DRUG PRODUCT" MEANS A DRUG PRODUCT
4	IN THE OPIOID ANALGESIC DRUG CLASS PRESCRIBED TO TREAT MODERATE
5	TO SEVERE PAIN OR OTHER CONDITIONS, WHETHER IN IMMEDIATE RELEASE
6	OR EXTENDED RELEASE OR LONG-ACTING FORM, THAT MAY BE COMBINED
7	WITH OTHER DRUG SUBSTANCES TO FORM A SINGLE DRUG PRODUCT OF
8	DOSAGE FORM.
9	SECTION 2. Safety clause. The general assembly hereby finds
10	determines, and declares that this act is necessary for the immediate
11	preservation of the public peace, health, and safety.

-3-